Brivaracetam Quantitative, Serum or Plasma
Also known as: BRIVARA SP
Use
This test measures the concentration of Brivaracetam in serum or plasma to monitor therapeutic levels and support seizure control in patients. Brivaracetam, marketed under the trade name Briviact, is an anticonvulsant drug used for the treatment of partial-onset seizures. Maintaining a therapeutic concentration in the patient's serum or plasma is crucial for effective seizure management, with recommended steady-state concentrations ranging from 0.2 to 2.0 mcg/mL.
Special Instructions
The test is not performed at ARUP Laboratories, so separate specimens must be submitted for this test when ordered alongside others. The test is conducted through a partner lab, NMS Labs, and follows CLIA regulations.
Limitations
The test's performance characteristics, including accuracy and precision, have been developed by NMS Labs. However, it has not been cleared or approved by the US Food and Drug Administration, which may affect its acceptance in certain clinical settings. Make sure to interpret results within the context of each patient's clinical condition and other specific factors.
New York Approved
Methodology
Mass Spectrometry
Biomarkers
LOINC Codes
- 88894-1
Result Turnaround Time
5-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.2 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Collect using plain red, lavender (K2EDTA or K3EDTA), or pink (K2EDTA) tubes. Separate from cells as soon as possible or within 2 hours of collection.
Storage Instructions
Refrigerated transport is preferred; stability is 1 month at room temperature or refrigerated and 4 months if frozen.
Causes for Rejection
Separator tubes.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 1 month |
| Refrigerated | 1 month |
| Frozen | 4 months |